Compare Quest Diagnostics Inc (DGX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while Vanguard Short Term Corporate Bond ETF trades at $78.72. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | VCSH | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Fixed Income |
52-Week High | $216.02 | $80.20 |
52-Week Low | $166.42 | $78.45 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VCSH trades at $78.45, down 0.2% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.29-$0.30 per share. Media coverage highlights VCSH's competitive yield advantage over similar short-term bond ETFs and its appeal for income-focused investors seeking corporate bond exposure with low expense ratios.
The outlook remains cautious given the Federal Reserve's indication that rate cuts are unlikely in 2026, which may pressure short-term bond performance. VCSH offers higher yields than treasury alternatives but carries additional credit risk. Institutional activity shows mixed positioning, with some firms increasing stakes while others reduce exposure amid interest rate uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
